Inside Diagnostics Webinar with Dr. Emma Howard from St Mary’s Hospital in Manchester
In the first half of 2017, AstraZeneca will be hosting three 1-hour live webinars with internationally recognized experts in BRCA testing. These webinars are intended for medical professionals wanting to increase their diagnostics expertise and knowledge. Each webinar will focus on a specific aspect of BRCA testing and will allow attendee’s the opportunity to ask questions and discuss challenges with world-leading experts.
You are invited to the first 1-hour live streamed webinar by Dr Emma Howard that will provide expert opinion on the best practice for BRCA variant classification. This webinar will:
A Q&A session will be included at the conclusion of the session; you can submit your questions at the start or during the webinar.
Dr. Emma Howard from St Mary’s Hospital in Manchester has more than 20 years experience, Dr Howard has performed over 6000 BRCA tests. She is most notably recognised for her understanding and interpretation of BRCA variants, classifying more than 500 variants of unknown clinical significance. Emma has dedicated time outside the laboratory to deliver internal and external training courses on unclassified variant interpretation, in addition to being a designated speaker for educational meetings. Attendees will be able to submit questions to Emma live during the meeting (via chat and phone), at which she will spend 20-25 minutes ensuring that the most pertinent questions are answered directly on the day.
Diagnostics Manager AstraZeneca
NS Approval ID 1025311 Revision date 12/2016
Other Inside Diagnostic Articles
About the Author
Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.